Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Comments

No comments yet. Be the first!